Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 266.25 -2.7 (-1%) Market Cap: 34.34 Bil Enterprise Value: 33.21 Bil PE Ratio: 0 PB Ratio: 1,065.00 GF Score: 78/100

Q1 2023 Alnylam Pharmaceuticals Inc Earnings Call Transcript

May 04, 2023 / 12:30PM GMT
Release Date Price: $205.39 (+2.95%)
Operator

Thank you for standing by, and welcome to the Alnylam Pharmaceuticals First Quarter 2023 Financial Results Conference Call. As a reminder, today's conference call is being recorded.

I would now like to turn the conference over to the company. Please go ahead.

Christine Regan Lindenboom
Alnylam Pharmaceuticals, Inc. - Senior VP of IR & Corporate Communications

Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today on the phone are: Yvonne Greenstreet, Chief Executive Officer; Tolga Tanguler, Chief Commercial Officer; Akshay Vaishnaw, President; and Jeffrey Poulton, Chief Financial Officer. Also in the room and available for Q&A is Pushkal Garg, our Chief Medical Officer.

For those of you participating via conference call, the slides can be accessed by going to the Events section of the Investors page of our website, investors.alnylam.com/events.

During today's call, as outlined in Slide 2, Yvonne will offer some introductory remarks and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot